This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
A phase I trial reported positive results for an antibody–drug conjugate that targets HER2-positive tumors. Trastuzumab duocarmazine, which kills tumor cells by causing DNA damage, induced partial responses in 33% of patients whose tumors were resistant to the approved antibody–drug conjugate trastuzumab emtansine. The drug caused fatigue, neutropenia, pneumonitis, and eye-related side effects.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't.
Published OnlineFirst August 2, 2019
doi: 10.1158/2159-8290.CD-NB2019-089
New ADC Shrinks HER2-Positive Tumors
Jump to section
Advertisement